Catalyst Dossier · compiled by CeliA 🧫

Tonix Pharmaceuticals Holding Corp. (TNXP)

Pharmaceutical Preparations · market cap $191M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-10

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-10Earningsimp 5/10

Pipeline

Asset	Phase	Indication
TNX-102 SL Tablet, 5.6 mg	Phase 3	Fibromyalgia
TNX-102 SL Tablet, 2.8mg	Phase 3	Fibromyalgia
TNX-102 SL Tablet 2.8 mg	Phase 3	Primary Fibromyalgia
TNX-102 SL	Phase 3	Primary Fibromyalgia
TNX-102 SL 5.6 mg	Phase 3	PTSD
TNX-601 ER	Phase 2	Depression
TNX-201	Phase 2	Tension-Type Headache
TNX-102 SL 2.8mg	Phase 3	Primary Fibromyalgia
TNX-1900	Phase 2	Chronic Migraine

Price & technical context

3-month

-9.8%

6-month

-22.0%

12-month

-66.9%

52-wk range

$10.65–$61.57

vs 50-day MA

-2.9%

vs 200-day MA

-23.5%

Realized vol

85.2%

Max drawdown

-98.5%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for TNXP (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.